A Review Paper on- In Vitro Evaluation of Vinblastine's Anticancer Activity Against Human Breast Cancer Cell Lines

Abstract

This comprehensive 2024 study systematically evaluated the synergistic nanticancer effects of vinblastine combined with silibinin against the MDA-MB-231 triple-negative breast cancer cell line, which is highly relevant to your thesis. Using MTT assays across a wide concentration range, researchers demonstrated that the combination significantly reduced cell viability compared to vinblastine monotherapy, achieving a combination index (CI) of 0.69 indicating strong synergism. Western blot analysis revealed dramatic upregulation of pro-apoptotic Bax protein (3-fold increase) and cleaved caspase-3 (3.5-fold), alongside downregulation of anti-apoptotic Bcl-2 (2-fold decrease). Flow cytometry with YO-PRO-1/PI double staining confirmed significantly elevated early and late apoptosis rates. Breast cancer, a hormonally influenced neoplasm originating from mammary epithelial cells— primarily ductal or lobular progenitors—dominates global oncology statistics as the most common malignancy in women and the secondleading cause of cancer death worldwide